Publisher Summary It is known for some time that malignant transformation of human cells
may be associated with the appearance of tumor associated antigens (TAA). Decades of …

The idea that tumors must “escape” from immune recognition contains the implicit
assumption that tumors can be destroyed by immune responses either spontaneously or as …

Genetically engineered T cell therapy can induce remarkable tumor responses in
hematologic malignancies. However, it is not known if this type of therapy can be applied …

In the past decade, basic studies in animal models have begun to elucidate the
physiological barriers which impede a successful antitumor immune response. These …

Given the vast number of genetic and epigenetic changes associated with carcinogenesis, it
is clear that tumors express many neoantigens. A central question in cancer immunology is …

Most major advances in human cancer immunology and immunotherapy have come from
studies in melanoma. We are beginning to understand the immune repertoire of T cells and …

Dendritic cells (DCs) have been shown to enhance anti-tumor immune responses in several
preclinical models. Furthermore, DC-like function can be elicited from peripheral blood …

Aim We investigated whether tumor-specific CD8+ T-cell responses affect tumor-free
survival as well as the relationship between CD8+ T-cell responses against tumor …

Purpose: To investigate the potential of the DNA hypomethylating agent 5-aza-2′-
deoxycytidine (5-aza-CdR) to improve the effectiveness of immunotherapeutic approaches …

Whole-cell tumor vaccines have been investigated for more than 20 years for their efficacy in
both preclinical models and in clinical trials in humans. There are clear advantages of whole …